Biocept (BIOC) Reports Q1 Loss Per Share of $0.37
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Biocept Reports First Quarter 2015 Financial Results
May 12, 2015 4:05 PM EDTAnnounces Increased Revenues and Strong Year-over-Year Growth in Test Volume
Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today reported financial results for the three months ended March 31, 2015.
Recent Business Highlights
Expanded the Company's non-small cell lung cancer (NSCLC) diagnostic capabilities to... More